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Abstract
Purpose To review the ability of current
imaging technologies to provide estimates of
rates of structural change in glaucoma
patients.
Patients and methods Review of literature.
Results Imaging technologies, such as
confocal scanning laser ophthalmoscopy
(CSLO), scanning laser polarimetry (SLP), and
optical coherence tomography (OCT), provide
quantifiable and reproducible measurements
of the optic disc and parapapillary retinal
nerve fibre layer (RNFL). Rates of change as
quantified by the rim area (RA) (for CSLO)
and RNFL thickness (for SLP and OCT) are
related to glaucoma progression as detected by
conventional methods (eg, visual fields and
optic disc photography). Evidence shows that
rates of RNFL and RA loss are significantly
faster in progressing compared with non-
progressing glaucoma patients.
Conclusion Measurements of rates of optic
disc and RNFL change are becoming
increasingly precise and individualized.
Currently available imaging technologies have
the ability to detect and quantify progression
in glaucoma, and their measurements may be
suitable end points in glaucoma clinical trials.
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published online 7 January 2011
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Introduction
Glaucoma is a complex and progressive disease
characterized by an optic neuropathy that is
usually associated with typical visual function
loss.1 Although most glaucoma patients will
show some evidence of progression, if followed
long enough, the rate of deterioration can be
highly variable among them. Some patients may
progress slowly over the course of many years
or decades with minimal impact on the quality
of vision, whereas others may have aggressive
disease with rapid rates of change that can
eventually result in blindness or substantial
impairment unless appropriate interventions
take place. Therefore, the evaluation of rates of
change in glaucoma is essential to allow proper
allocation of resources towards the patients who
are most likely to develop impairment. In fact,
according to the Consensus on Medical
Treatment from the World Glaucoma
Association, glaucoma treatment is indicated for
patients whose rates of progression will most
likely result in loss in vision-related quality of
life over the projected remaining years of life.2
A complete assessment of rates of disease
progression requires both structural and
functional measures, as it is known that many
patients seem to progress by one method and
not the other.3–6 Although functional outcomes
have an unquestionable relevance to patients,
it has been shown that structural changes can
often precede functional losses and be an earlier
marker of deterioration. More importantly, a
recent study showed that structural changes
observed on optic disc stereophotographs are
predictive of future functional losses and,
therefore, carry clinically relevant prognostic
information.7 However, although optic disc
stereophotographs have been considered the
gold standard for evaluation of structural
damage in glaucoma, evaluation of rates of
structural change using stereophotographs is
difficult because of the qualitative and
subjective nature of this assessment.
Over the past two decades, several
technologies, such as confocal scanning laser
Received: 17 November 2010
Accepted: 22 November 2010
Published online: 7 January
2011
1Department of Ophthalmology,
Hamilton Glaucoma Center,
University of California
San Diego, La Jolla, CA, USA
2Glaucoma sector, Division of
Ophthalmology, University of
Geneva, Geneva, Switzerland
3Department of
Ophthalmology, Universidade
Federal de Sa˜o Paulo,
Sa˜o Paulo, Brazil
4Department of
Ophthalmology and Visual
Sciences, The Chinese
University of Hong Kong,
Hong Kong, Hong Kong
Correspondence:
RN Weinreb, Department of
Ophthalmology, Hamilton
Glaucoma Center, University of
California San Diego, 9500
Gilman Drive 0946,
La Jolla, CA 92093, USA
Tel: þ 1 858 534 8824;
Fax: þ1 858 534 1625.
E-mail: weinreb@
eyecenter.ucsd.edu
Eye (2011) 25, 269–277
& 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11
www.nature.com/eye
C
A
M
B
R
ID
G
E
O
P
H
T
H
A
L
M
O
L
O
G
IC
A
L
S
Y
M
P
O
S
IU
M
ophthalmoscopy (CSLO), scanning laser polarimetry
(SLP), and optical coherence tomography (OCT), have
been used to quantitatively and objectively measure the
topography of the optic disc and thickness of the
parapapillary retinal nerve fibre layer (RNFL).8 Results
from these imaging technologies can be used to predict
glaucoma development,9–13 and have the potential to
detect and measure structural progression.7,14–24 Recent
literature has focused on the ability of these instruments
to provide estimates of rates of change over time. In this
review, we discuss the evidence with regard to the ability
of current imaging technologies in measuring rates of
structural change in glaucoma and their relationship to
conventional methods for assessment of disease
progression.
CSLO
CSLO was introduced more than 20 years ago. It enables
reproducible measurements of the surface height of the
optic nerve head (ONH) and parapapillary retina.9
The most recent implementation of this technology
(Heidelberg Retina Tomograph (HRT), Heidelberg
Engineering GmbH, Heidelberg, Germany) has been
widely used to evaluate topographic changes of the ONH
to detect progression of glaucoma.13,24–26 Although
different stereometric parameters have been suggested as
useful markers of progression, some studies have
suggested that the neuroretinal rim area (RA) is the most
reliable and reproducible measure for detection of
change.27,28 Changes in RA have been demonstrated in
glaucoma patients followed over time and are associated
with disease progression.14,15,22,28–34 Baseline measure-
ments obtained by the HRT have also been shown to
predict future conversion to glaucoma in patients
suspected of having the disease, although the predictive
accuracy of the measurements on individual patients is
generally low.13
CSLO measurements have been used to evaluate rates
of glaucoma progression in several studies. Strouthidis
et al22 initially used rates of change in RA to compare
detection of progression by visual fields and CSLO in
patients with ocular hypertension. They did not,
however, report absolute values of change. See et al,33
observing 94 glaucoma patients and 54 normal controls
over 8.6±2.9 years, found a rate of change (RA loss/
year) of 0.0053 and 0.0012 mm2/year, respectively
(Figure 1). Strouthidis et al35 found that the rate of RA
loss was greatest in the inferotemporal (1.43%/year)
and superotemporal sectors (1.05%/year). Poli et al36
also assessed rates of change with the CSLO. In 31
subjects with ocular hypertension and reproducible
visual field loss and 19 normal subjects, they reported
global RA mean slopes of 0.0123 mm2/year.
Alencar et al15 studied 629 eyes of 390 patients. Over an
average of 3.3±0.7 years of follow-up, the average rate of
RA decline was not significantly different between
glaucoma progressors and non-progressors (0.0058 vs
0.0073 mm2/year, respectively; P¼ 0.727). The area
under the receiver-operating characteristic (ROC) curve
for this parameter showed a poor discriminatory ability,
no better than chance. However, when eyes that had
undergone glaucoma surgery were excluded, the rates
of RA loss became significantly different between
progressors (0.020 mm2/year) and non-progressors
(0.007 mm2/year; P¼ 0.015). This is probably explained
by the effect of intraocular pressure (IOP) reduction in
causing a significant reversal of ONH cupping, which
may be interpreted as an increase in RA by the CSLO
and confound evaluation of RA change in patients
who underwent surgery during follow-up.29,37,38
A shortcoming of the CSLO technology stems from the
variation induced by tracing a contour line to outline
the optic disc. Alternative approaches for detecting
progression in series of CSLO images, such as the
topographic change analysis,26,31,39,40 the glaucoma
probability score,14,25,41,42 and statistic image
mapping,43,44 have been developed and obviate the need
for a contour line. These methods, however, exhibit
only moderate agreement with each other and have
poor agreement with expert-assessed change in optic
disc stereophotographs.45
In the context of detecting progressive glaucoma, one
advantage of the CSLO, when comparing it to other
imaging devices, is that latest commercially available
versions of the instrument have shown relatively good
compatibility with older ones, which is of significant
benefit to clinicians and researchers who need to follow
up patients for long periods of time.
SLP
SLP (GDx; Carl Zeiss Meditec Inc., Dublin, CA, USA)
is a confocal scanning laser ophthalmoscope with an
integrated polarimeter that measures the amount of
retardation (phase shift) of a polarized near-infrared laser
beam as it passes through the RNFL.45 Changes in RNFL
have been suggested to be the earliest sign of glaucoma
development in many patients and to precede visual
field loss.46 The SLP enables clinicians to evaluate the
parapapillary RNFL objectively and quantitatively. This
technology has been shown to provide reproducible
RNFL measurements and to differentiate glaucoma
patients from normal subjects with sensitivities and
specificities between 72 and 78%, and 56 and 92%,
respectively.47–52
Imaging artifacts such as a poorly compensated
corneal birefringence can hamper the accuracy of the
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device in clinical practice.53 The introduction of a
variable corneal polarization compensator (GDxVCC)
attempted to alleviate this problem and resulted in
improved diagnostic accuracy.54 The GDxVCC scans,
however, were found to be limited by atypical
retardation patterns (ARPs). ARPs result from poor
noise-to-signal ratio as a consequence of light scattering
in the eye. Medeiros et al18 have shown that the presence
of ARP on SLP scans adversely affects the detection
of progressive glaucomatous RNFL loss. The most
recent commercially available version (GDxPRO) is a
modification of the GDxVCC and provides an enhanced
corneal compensation (ECC) to eliminate artifacts
associated with ARP.54,55
The GDx software has been recently upgraded with
the addition of a guided progression analysis (GPA).
The GPA software compares SLP images acquired
during follow-up and reports a summary analysis for
progression in an individual eye after automated
consideration of the expected test–retest variability. It has
been shown to be able to identify a significant proportion
of glaucoma progression with 50% sensitivity and 96%
specificity compared with optic disc stereophotographs
and visual fields.16 Repeatability of GDxVCC was
demonstrated to be stable for all stages of disease
severity with a repeatability coefficient within 4mm
(compared with 6 mm with Stratus OCT, Carl Zeiss
Meditec Inc.).42
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Figure 1 Disc and field progression in subject 9. (a) Visual field grey scale at the conclusion of the study; the hatched squares indicate
the test points flagged as progressing according to the standard PLR criteria; (b) HRT baseline mean topography; (c) HRT mean
topography at the conclusion of the study period. (d–g) Scatterplots with regression line for sectoral RA against time. (From
Strouthidis et al22).
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Recently, several authors calculated rates of change for
the GDx. Using GDxVCC, Medeiros et al17 imaged
individuals with suspected and established glaucoma.
They reported an average loss of RNFL thickness of
0.70 mm/year in glaucoma progressors (based on GPA
software for standard automated perimetry (SAP)) vs
0.14 mm/year in non-progressors (Po0.001), very
similar to rates of change reported elsewhere by the
same group (0.65 and 0.11mm/year, respectively).15
Da Pozzo et al,56 in a cross-sectional design estimated the
age-related loss of RNFL thickness in 384 healthy adults
and found a rate of 0.08mm/year attributed to ageing.
To date, four longitudinal studies have evaluated
GDxECC for detection of progression in glaucoma, with
two of them comparing measurements obtained by
GDxECC with GDxVCC.19,21,57,58 Medeiros et al19
evaluated the relationship between IOP and progressive
RNFL loss in a cohort recruited from the Diagnostic
Innovations in Glaucoma Study (DIGS). Patients who
manifested progression of glaucoma on SAP–GPA
showed a significantly higher rate of RNFL change
compared with non-progressors (0.95 vs 0.17mm/year;
P¼ 0.001). Considering an average baseline thickness of
47 mm for the RNFL, this amount of loss in progressors
would represent an almost 2% loss per year. Each
1-mmHg higher IOP was associated with an additional
RNFL loss of 0.13 mm/year in progressors compared with
0.05 mm/year overall. They further showed that rates of
change were higher in inferior and temporal sectors,
which is in agreement with the expected pattern of
glaucomatous damage to the RNFL and to the
neuroretinal rim (Figure 2).59 The same investigators in a
subsequent publication reported an average rate of
decline for RNFL thickness measurements of
1.24 mm/year in progressors vs 0.34 mm/year in
non-progressors, with a significantly higher area under
the ROC curve for detecting change for ECC compared
with VCC (0.89 vs 0.65; Po0.001) (Figure 3).21 Grewal
Figure 2 Radar plot illustrating the rates of change in SLP with
ECC retinal nerve fibre layer measurements according to the
sectors around the optic disc. Eyes that showed progression on
visual fields and/or optic disc stereophotographs had greater
loss of the RNFL in the inferior and superior sectors. I, inferior;
N, nasal; S, superior; T, temporal. (From Medeiros et al19).
Figure 3 Scatterplot illustrating the relationship between rates of change in the SLP with ECC parameter temporal–superior–nasal–
inferior–temporal average and IOP. Rates of change are shown for eyes that progressed by visual fields and/or stereophotographs
(progressors) as well as for eyes that did not (non-progressors). (From Medeiros et al19).
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et al57 demonstrated that ECC identified more cases of
progression than VCC (11.8 vs 8.8%), with only moderate
agreement (k¼ 0.57). In a subsequent publication,58 the
same investigators using ECC found rates of annual
RNFL loss of 1.11 mm/year (progressors) vs
0.41 mm/year (non-progressors), when progression was
defined based on the SAP visual field index.
A significant limitation of SLP is the lack of
interchangeability among serial generations of the
commercial instrument. RNFL thickness measurements
obtained with the GDxVCC and GDxECC are not
interchangeable. Thus, a new baseline must be
established in the case of conversion to GDxECC.
OCT
OCT is a non-contact and non-invasive technique for
examination of the human retina. Briefly, the instrument
uses a super luminescent diode light and works similar
to a B-scan ultrasound, using light instead of sound.
Unlike the CSLO and the SLP, OCTs are currently
available from several different manufactures, with
different axial resolution and lower acquisition time.
We focus, herein, on the Stratus OCT because very
little longitudinal data are currently available for the
spectral-domain OCTs.
Wollstein et al60 showed the potential use of OCT in
detecting glaucomatous progression with an event-based
approach (ie, a change greater than the expected
variability was considered progression). Using a
prototype, they concluded that the OCT was more
sensitive than standard visual fields for the detection
of progression. In fact, 22% of eyes had a significant
change measured by the OCT without corresponding
deterioration of the visual fields. However, it was not
clear whether these eyes were true progressors
undetected by visual fields or false positives due to
variability of the measurements or age-related thinning
of the RNFL.
Medeiros et al20 evaluated the ability of RNFL
thickness, ONH, and macular thickness measurements to
detect glaucomatous progression. In their study,
progression was determined by SAP and longitudinal
assessment of optic disc stereophotographs. They
reported the RNFL thickness parameters as having better
ability than ONH and macular thickness parameters to
detect progression (Figure 4). This is in agreement with
previous cross-sectional studies that showed a poor
performance of Stratus OCT-derived macular and ONH
parameters for cross-sectional detection of glaucoma.61
For average RNFL thickness, a rate of change of 0.72 mm
(B1%)/year for the progressors compared with
0.14mm/year in non-progressors was reported. The
authors found a wide variation of rates of change, which
has also been reported by Leung et al62 in a study
evaluating the GPA software of Stratus OCT. Although this
wide range can be explained by individual characteristics,
such as stage of disease and response to treatment,
it is possible that non-centered scans and signal strength
affected the ability to detect change.63,64 Nonetheless, the
wide individual variation should be considered when
evaluating patients on a case-by-case basis.
Figure 4 ROC curves of rates of change for discriminating progressors from non-progressors of the three parameters with largest
areas under the ROC curves in each scanning area and the average RNFL thickness. (From Medeiros et al20).
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The recent introduction of spectral domain OCT
(SDOCT) has enhanced resolution and decreased scan
acquisition time compared with Stratus OCT. With more
reproducible images,65,66 there is potential for improved
ability to detect glaucomatous progression. Further, with
this higher resolution, new scan types are now possible.
One example is the ganglion cell complex (GCC) that
selectively measures the inner retina in the macular
region. The GCCs have shown similar diagnostic accuracy
for detecting glaucoma as the RNFL thickness, and may be
useful for monitoring the disease.67 Recently, Leung et al
(Leung CK et al, personal communication) evaluated the
ability to detect RNFL progression using Stratus OCT and
SDOCT. A total of 128 eyes were followed for a minimum
of 24 months. They found more progressors using SDOCT
compared with Stratus OCT (23.5% of patients with
SDOCT vs 4.9% with Stratus OCT). The agreement with
visual field progression was also better with SDOCT. In
addition, five eyes had an increasing RNFL thickness with
Stratus OCT, indicating an inherent measurement
variability of the instrument. The agreement for detection
of RNFL progression was poor between the two
instruments (k¼ 0.188). The rate of change ranged
between 1.52 and 5.03mm/year with SDOCT, and
between 2.22 and 7.60mm/year with Stratus OCT.
Table 1 summarizes the ability of all the three imaging
technologies to provide rates of change.
Summary and future directions
Currently available imaging technologies have been
demonstrated to detect and quantify glaucomatous
progression in a reproducible manner. Rates of change in
RNFL thickness and optic disc topographic
measurements as measured by different instruments
have been shown to correlate significantly with
conventional methods for assessment of change, such as
SAP and optic disc stereophotographs. Several studies
have shown that rates of structural damage are faster in
eyes with progressive glaucoma, and show a correlation
with important risk factors for the disease such as IOP.
Advances in the assessment of change with imaging
devices may shift the macroscopic standard of optic
disc photographs towards the microscopic and
three-dimensional imaging of the retinal layers. With
the increasing resolution and reliability of imaging
technologies, it is likely that the estimation of these rates
of change will be more precise and individualized in the
near future. In addition, advances and implementation
of image stabilization technologies should improve
reproducibility of structural measurements to enable
better differentiation of variability from true progression.
At present, the Food and Drug Administration (FDA)
recognizes IOP as an efficacy end point for IOP-lowering
drugs and visual field testing, visual acuity, contrast
sensitivity, and colour vision as functional end points.68
IOP is an imperfect surrogate for the clinical outcomes of
glaucoma, as disease can progress despite low IOP or
remain stable despite IOP levels considered high.69–71
The use of visual fields as an end point is potentially
limited by the need for large samples, long follow-up,
variability of results, and inconsistency in criteria for
defining progression.72 The absence of regulatory
support for other glaucoma end points has been
Table 1 Mean rates of change for patients with progressive glaucoma as measured by CLSO, SLP (GDxVCC and GDxECC), and
Stratus OCT
Imaging technology Study Parameter Mean rates of change AROC
Progressors Non-progressors
CSLO Alencar et al1 RA average (mm2/year) 0.0058 0.0073 0.51 (95% CI, 0.40–0.61)
Poli et al2a RA average (mm2/year) 0.0123 NA NA
See et al3 RA average (mm2/year) 0.0053 0.0012 NA
GDxECC Medeiros et al4 TSNIT average (mm/year) 0.95 0.17 NA
Medeiros et al5 TSNIT average (mm/year) 1.24 0.34 0.89 (95% CI, 0.83–0.95)
Grewal et al6b TSNIT average (mm/year) 1.11 0.41 NA
GDxVCC Medeiros et al7c TSNIT average (mm/year) 0.70 0.14 NA
Medeiros et al5d TSNIT average (mm/year) 0.46 0.15 0.65 (95% CI, 0.53–0.77)
Alencar et al1 TSNIT average (mm/year) 0.65 0.11 0.81 (95% CI, 0.74–0.88)
Stratus OCT Medeiros et al8 TSNIT average (mm/year) 0.72 0.14 0.83 (95% CI, 0.72–0.92)
Leung et al9 TSINT average (mm/year) 3.30 (median) NA NA
Abbreviations: AROC, area under the receiver operating characteristic curve; ARP, atypical patterns of retardation; CI, confidence interval; CLSO,
confocal scanning laser ophthalmoscopy; ECC, enhanced corneal compensation; NA, not applicable; OCT, optical coherence tomography; RA, rim area;
SAP, standard automated perimetry; SLP, scanning laser polarimetry; TSNIT, temporal–superior–nasal–inferior–temporal.
aCalculated for ‘converters’ (defined as normal or ocular hypertensive subjects who progressed to glaucoma).
bProgression was defined by the slope of the visual field index on SAP.
cIncluded scans with ARP.
dExcluded scans with ARP.
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identified as a weakness in exploring candidate agents
for neuroprotective therapy and alternative surrogate
end points have been sought. Structural measurements
obtained by imaging technologies have the potential to
overcome these obstacles, and could potentially act as
useful biomarkers and surrogate end points to be used in
glaucoma clinical trials. Future research should be
directed at evaluating, quantifying, and comparing the
abilities of structural change measured by different
imaging technologies in predicting clinically relevant
outcomes in glaucoma.
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